Brief: 9 Meters Biopharma Announces Positive Topline Data For NM-002 In Phase 1B/2A Trial For Short Bowel Syndrome

9 Meters Biopharma

07/12/2020 12:54

Dec 7 (Reuters) - 9 Meters Biopharma Inc  NMTR.O :
    * 9 METERS BIOPHARMA, INC. ANNOUNCES POSITIVE TOPLINE DATA
FOR
NM-002, A PROPRIETARY LONG-ACTING GLP-1, IN PHASE 1B/2A TRIAL
FOR SHORT BOWEL SYNDROME
    * 9 METERS BIOPHARMA INC - RAPID ONSET AND SUSTAINED
CLINICAL
EFFECT FOLLOWING FIRST DOSE IN ALL 9 PATIENTS IN TOTAL STOOL
OUTPUT (TSO) VOLUME
    * 9 METERS BIOPHARMA INC - CLINICALLY RELEVANT IMPROVEMENTS
IN TSO
VOLUME AND BOWEL MOVEMENT FREQUENCY
    * 9 METERS BIOPHARMA INC - TWICE-MONTHLY FIXED-DOSING
REGIMEN
EXHIBITED AN EXCELLENT SAFETY AND TOLERABILITY PROFILE
    * 9 METERS BIOPHARMA INC - PLAN TO MEET WITH FDA AS SOON AS
POSSIBLE IN FIRST QUARTER OF 2021 TO DISCUSS NEXT STEPS FOR
CLINICAL DEVELOPMENT OF NM-002

Source text: (https://bit.ly/33Rg135)
Further company coverage:  NMTR.O 

 ((Reuters.Briefs@thomsonreuters.com;))